Acarbose Bioequivalence: Exploration of New Pharmacodynamic Parameters
Journal Title: The AAPS Journal - Year 2012, Vol 14, Issue 2
Abstract
To investigate bioequivalence (BE) testing of an acarbose formulation in healthy Chinese volunteers through the use of recommended and innovative pharmacodynamic (PD) parameters. Following the Food and Drug Administration (FDA) guidance, a randomized, cross-over study of acarbose test (T) and reference (R) (Glucobay®) formulations was performed with a 1-week wash-out period. Preliminary pilot studies showed that the appropriate dose of acarbose was 2 × 50 mg, and the required number of subjects was 40. Serum glucose concentrations after sucrose administration (baseline) and co-administration of sucrose/acarbose on the following day were both determined. Three newly defined PD measures of glucose fluctuation (glucose excursion (GE), GE′ (glucose excursion without the effect of the homeostatic glucose control), and fAUC (degree of fluctuation of serum glucose based on AUC)), the plateau glucose concentration (Css), and time of maximum reduction in glucose concentration (Tmax) were tested in the evaluation. The adequacy of the two parameters recommended by the FDA, ΔCSG,max (maximum reduction in serum glucose concentration) and AUEC(0-4h) (reduction in the AUC(0-4h) of glucose between baseline and acarbose formulation) was also evaluated. The Tmax values were comparable, and the 90% confidence intervals of the geometric test/reference ratios (T/R) for ΔCSG,max, Css, GE, and fAUC were all within 80–125%. The parameter GE′ was slightly outside the limits, and the parameter AUEC(0-4h) could not be computed due to the presence of negative values. In acarbose BE evaluation, while the recommended parameter ΔCSG,max is valuable, the combination of Css and one of the newly defined glucose fluctuation parameters, GE, GE’, and fAUC is preferable than AUEC(0-4h). The acarbose test formulation can be initially considered to be bioequivalent to Glucobay®.
Authors and Affiliations
Min Zhang, Jin Yang, Lei Tao, Lingjun Li, Pengcheng Ma, John Paul Fawcett
Keywords
Related Articles
- EP ID EP681211
- DOI 10.1208/s12248-012-9341-x
- Views 76
- Downloads 0
Challenges and Opportunities in Establishing Scientific and Regulatory Standards for Assuring Therapeutic Equivalence of Modified Release Products: Workshop Summary Report
Modified release products are complex dosage forms designed to release drug in a controlled manner to achieve desired efficacy and safety. Inappropriate control of drug release from such products may result in reduced ef...
Nanoparticles Containing Anti-inflammatory Agents as Chemotherapy Adjuvants: Optimization and In Vitro Characterization
The pre-administration of dexamethasone (DEX) has previously been shown to enhance the anti-tumor efficacy of chemotherapeutic agents. The delivery of anti-inflammatory agents specifically to tumors via nanoparticle carr...
Recent Advances in Application of Pharmacogenomics for Biotherapeutics
Biotherapeutics (BTs), one of the fastest growing classes of drug molecules, offer several advantages over the traditional small molecule pharmaceuticals because of their relatively high specificity, low off-target effec...
The venus flytrap of periplasmic binding proteins: An ancient protein module present in multiple drug receptors
Located between the inner and outer membranes of Gram-negative bacteria, periplasmic binding proteins (PBPs) scavenge or sense diverse nutrients in the environment by coupling to transporters or chemotaxis receptors in t...
Integrated Pharmacokinetic-Driven Approach to Screen Candidate Anticancer Drugs for Brain Tumor Chemotherapy
The online version of this article (doi:10.1208/s12248-012-9428-4) contains supplementary material, which is available to authorized users.